#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neonatal alloimmune thrombocytopenia Nephropathy Congenital cystic kidney disease Growth hormone deficiency Acute myeloid leukaemia recurrent Hereditary ataxia Rett syndrome Lymphangiosarcoma Cutaneous T-cell lymphoma refractory Turner's syndrome Biliary cancer metastatic IPEX syndrome Pulmonary arterial hypertension Phaeochromocytoma Squamous cell carcinoma of the oral cavity More trials…

    Learn about Rare Diseases

    Breast angiosarcoma metastatic Isodicentric chromosome 15 syndrome – Life with Disease Adrenocortical carcinoma – Treatment Congenital nephrogenic diabetes insipidus – Diagnostics Glycogen storage disease type I Congenital hypotransferrinaemia – Basic Information Prader-Willi syndrome – Treatment Alternating hemiplegia of childhood – Life with Disease Piriformis syndrome – Trials in Disease Hyperoxaluria More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    [18F]DED Batoclimab Tozinameran Azd8205 Lifileucel Desoximetasone Metformin Lisinopril Dihydrate Olive Oil, Refined Atenolol Rilvegostomig Tisagenlecleucel Inebilizumab Doxribtimine HUPERZINE A Tx200-Tr101 Gallium (68Ga) Gozetotide Namilumab Permethrin DESMOPRESSIN ACETATE More therapies…

    Learn about Your Condition

    Circulatory collapse Endometrial cancer Cutaneous T-cell lymphoma Procedural pain Liposarcoma Transferrin decreased Hepatitis alcoholic Lyme disease Atrial septal defect Nodular melanoma Cortical dysplasia Stargardt's disease Pyrexia Ear discomfort Myxofibrosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer metastatic

  • Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Goserelin Acetate
    • Letrozole
    • Tamoxifen
    Greece Italy Poland Portugal Spain

  • Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Trastuzumab
    • Trastuzumab Emtansine
    Belgium The Netherlands

  • Study of Nivolumab After Initial Treatment in Patients with Metastatic Triple-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Nivolumab
    The Netherlands

  • Study on Nivolumab and Cisplatin for Patients with Metastatic Triple Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Cisplatin
    • Nivolumab
    The Netherlands

  • Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Breast cancer male
    • Breast cancer metastatic
    Investigated Drugs:
    • Olaparib
    • Pembrolizumab
    Germany

  • Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Atezolizumab
    • Carboplatin
    The Netherlands
Previous Page
1 … 5 6 7 8 9 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!